Home  »  News   »  Defying the odds and beating analyst forecasts: Pr...

Defying the odds and beating analyst forecasts: Protagonist Therapeutics Inc. (PTGX)

At the end of the latest market close, Protagonist Therapeutics Inc. (PTGX) was valued at $7.84. In that particular session, Stock kicked-off at the price of $7.78 while reaching the peak value of $7.94 and lowest value recorded on the day was $7.53. The stock current value is $7.60.Recently in News on November 16, 2022, Protagonist Therapeutics Reports Granting of Inducement Award. Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D., M.S., F.A.C.P., the Company’s recently hired Chief Medical Officer, in accordance with the terms of Dr. Molina’s employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022. You can read further details here

Protagonist Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $37.04 on 01/05/22, with the lowest value was $6.91 for the same time period, recorded on 06/14/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Protagonist Therapeutics Inc. (PTGX) full year performance was -78.09%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Protagonist Therapeutics Inc. shares are logging -79.48% during the 52-week period from high price, and 9.99% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.91 and $37.04.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 356023 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Protagonist Therapeutics Inc. (PTGX) recorded performance in the market was -77.78%, having the revenues showcasing -24.30% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 369.74M, as it employees total of 122 workers.

The Analysts eye on Protagonist Therapeutics Inc. (PTGX)

During the last month, 5 analysts gave the Protagonist Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.00, with a change in the price was noted -0.86. In a similar fashion, Protagonist Therapeutics Inc. posted a movement of -10.17% for the period of last 100 days, recording 840,369 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PTGX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of Protagonist Therapeutics Inc. (PTGX)

Raw Stochastic average of Protagonist Therapeutics Inc. in the period of last 50 days is set at 4.52%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 5.88%. In the last 20 days, the company’s Stochastic %K was 24.93% and its Stochastic %D was recorded 35.29%.

Considering, the past performance of Protagonist Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -77.78%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -3.31%, alongside a downfall of -78.09% for the period of the last 12 months. The shares increased approximately by -5.12% in the 7-day charts and went up by -8.98% in the period of the last 30 days. Common stock shares were lifted by -24.30% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts